Breaking News

PAREXEL to Acquire Health Advances

January 20, 2016

Expands strategic portfolio- and product-level commercialization consulting

PAREXEL has entered into a definitive agreement to acquire all outstanding equity of Health Advances, LLC, a consulting firm that combines clinical, scientific and business expertise to provide strategic advice to life sciences companies. The acquisition is expected to close in February, subject to customary closing conditions.

Health Advances employs approximately 120 scientists, clinicians, and business professionals in three main offices – two in the U.S. and one in Europe. It offers services such as portfolio planning, product positioning, market assessment and forecasting, strategic and business planning, as well as advising on partnering and acquisitions.

“Health Advances is a market-leading life sciences consultancy. Its innovative services, strong client relationships, and talented employees will complement our long-standing leadership in drug development, market access, and lifecycle management services for our clients,” said Josef von Rickenbach, chairman and chief executive officer, PAREXEL. “Health Advances will expand and strengthen our capabilities to meet the growing market demand for strategic portfolio- and product-level commercialization consulting. Clients will be able to engage with a single, global provider to fulfill all of their commercialization strategy and execution needs.”

“We are thrilled to be part of PAREXEL and offer clients a global presence, a larger range of services, and increased expertise in product and portfolio development. Together, we can maximize the value of our clients’ product and service portfolios,” said Mark Speers and Paula Ness Speers, co-founders of Health Advances.
  • CROs and Today’s  R&D Landscape

    CROs and Today’s R&D Landscape

    Kristin Brooks, Associate Editor, Contract Pharma||November 9, 2016
    John Lewis of ACRO discusses opportunities, challenges, and the future CRO

  • The Human Parts of Mouse Models

    The Human Parts of Mouse Models

    Julia Schueler, Head of in vivo Operations, Oncotest, a Charles River company ||October 11, 2016
    The PDX model system has come back into focus

  • Robust Assay Designs

    Robust Assay Designs

    Tim Wright, Editor, Contract Pharma||October 11, 2016
    Easing the transition from preclinical to clinical research